NCT06299124 2025-01-20A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid TumorsRegor Pharmaceuticals Inc.Phase 1 Active not recruiting40 enrolled